MVT-602 is an oligopeptide kisspeptin-1 receptor agonist and an investigational drug candidate for egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).
More than 200 study participants have received treatment with MVT-602 in Phase 1 and Phase 2 clinical trials.
MVT-602 is not approved by the FDA
Clinical Trial Results
MVT-602 is not approved by the FDA.
In October 2018, we presented data from a Phase 1 trial of MVT-602 at the American Society of Reproductive Medicine (ASRM) Scientific Congress. Results of this trial showed that administration of MVT-602 in 24 healthy premenopausal women in the follicular phase produced a dose-related increase in LH and expected post-dose increases in FSH and estrogen. In June 2019, we presented data from a Phase 2a trial of MVT-602 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. Results of this trial showed that the administration of MVT-602 produced an LH surge that approximated the natural mid-cycle LH surge and was associated with high rates of ovulation on ultrasound. Adverse events in these studies were similar between placebo and the MVT-602 groups with no apparent dose-related effects.
Recent News and Presentations
19 Nov 2019
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
18 Nov 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
12 Nov 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019